
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson is poised for long-term success as they continue to invest in new product launches and experience growth in their Pharmaceutical and Medical Devices segments. Despite legal challenges, their strong pipeline and disciplined approach to capital allocation make them a top performer in the MedTech industry. With a commitment to sustainability and an optimistic outlook for revenue and EPS, JNJ is a prudent investment for those seeking long-term growth and stability.
Bears say
Johnson & Johnson is a well-diversified healthcare company that has recently undergone restructuring and divestment to focus on its innovative medicine and medtech divisions. Despite potential for growth in key areas such as vision and cardiovascular products, there are several risks including loss of exclusivity for key drugs, potential challenges in the MedTech division, and ongoing litigations that could disrupt the company's operations. Furthermore, there is uncertainty surrounding the success of its sustainability initiatives and potential challenges with M&A and integration.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares